Best practice & research. Clinical endocrinology & metabolism最新文献

Role of B cells in intratumoral MBTA immunotherapy of murine pheochromocytoma model B 细胞在小鼠嗜铬细胞瘤模型瘤内 MBTA 免疫疗法中的作用

IF 7.4 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2024-09-11 DOI: 10.1016/j.beem.2024.101941

Ondrej Uher, Katerina Hadrava Vanova, Katerina Petrlakova, Rachael Labitt, Radka Lencova, Andrea Frejlachova, Juan Ye, Herui Wang, Michal Masarik, Jan Zenka, Zhengping Zhuang, Karel Pacak

{"title":"Role of B cells in intratumoral MBTA immunotherapy of murine pheochromocytoma model","authors":"Ondrej Uher, Katerina Hadrava Vanova, Katerina Petrlakova, Rachael Labitt, Radka Lencova, Andrea Frejlachova, Juan Ye, Herui Wang, Michal Masarik, Jan Zenka, Zhengping Zhuang, Karel Pacak","doi":"10.1016/j.beem.2024.101941","DOIUrl":"https://doi.org/10.1016/j.beem.2024.101941","url":null,"abstract":"Immunotherapy represents a revolutionary advancement in cancer treatment, which has traditionally focused on T cells; however, the role of B cells in cancer immunotherapy has gained interest because of their role in antigen presentation, antibody production, and cytokine release. In this study, we examined the role of B cells in previously developed intratumoral MBTA therapy (mannan-BAM, TLR ligands, and anti-CD40 antibody) in murine models of MTT pheochromocytoma. The results indicated that B cells significantly enhance the success of MBTA therapy, with wild-type mice exhibiting a lower tumor incidence and smaller tumors compared with B cell-deficient mice. Increased IL-6 and TNF-alpha levels indicated severe inflammation and a potential cytokine storm in B cell-deficient mice. Neutralization of TNF-alpha ameliorated these complications but resulted in increased tumor recurrence. The results highlight the important role of B cells in enhancing the immune response and maintaining immune homeostasis during MBTA therapy. Our findings offer new insights into improving therapeutic outcomes.","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":null,"pages":null},"PeriodicalIF":7.4,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142267228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent progress in molecular classification of phaeochromocytoma and paraganglioma 嗜铬细胞瘤和副神经节瘤分子分类的最新进展

IF 7.4 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2024-09-07 DOI: 10.1016/j.beem.2024.101939

Emma Boehm, Anthony J. Gill, Roderick Clifton-Bligh, Richard W. Tothill

{"title":"Recent progress in molecular classification of phaeochromocytoma and paraganglioma","authors":"Emma Boehm, Anthony J. Gill, Roderick Clifton-Bligh, Richard W. Tothill","doi":"10.1016/j.beem.2024.101939","DOIUrl":"https://doi.org/10.1016/j.beem.2024.101939","url":null,"abstract":"Phaeochromocytomas (PC) and paragangliomas (PG) are neural crest cancers with high heritability. Recent advances in molecular profiling, including multi-omics and single cell genomics has identified up to seven distinct molecular subtypes. These subtypes are defined by mutations involving hypoxia-inducible factors (HIFs), Krebs cycle, kinase and WNT signalling, but are also defined by chromaffin differentiation states. PCPG have a dominant proangiogenic microenvironment linked to HIF pathway activity and are generally considered “immune cold” tumours with a high number of macrophages. PCPG subtypes can indicate increased metastatic risk but secondary mutations in telomere maintenance genes or are required to drive the metastatic phenotype. Molecular profiling can identify molecular therapeutic (e.g. and ) and radiopharmaceutical targets while also helping to support variant pathogenicity and familial risk. Molecular profiling and subtyping of PCPG therefore confers the possibility of nuanced prognostication and individual treatment stratification but this still requires large-scale prospective validation.","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":null,"pages":null},"PeriodicalIF":7.4,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142267230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Overview of recent guidelines and consensus statements on initial screening and management of phaeochromocytoma and paraganglioma in SDHx pathogenic variant carriers and patients 关于 SDHx 致病变异携带者和患者中的嗜铬细胞瘤和副神经节瘤的初步筛查和管理的最新指南和共识声明概览

IF 7.4 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2024-09-07 DOI: 10.1016/j.beem.2024.101938

Charlotte Lussey-Lepoutre, Karel Pacak, Ashley Grossman, David Taieb, Laurence Amar

{"title":"Overview of recent guidelines and consensus statements on initial screening and management of phaeochromocytoma and paraganglioma in SDHx pathogenic variant carriers and patients","authors":"Charlotte Lussey-Lepoutre, Karel Pacak, Ashley Grossman, David Taieb, Laurence Amar","doi":"10.1016/j.beem.2024.101938","DOIUrl":"https://doi.org/10.1016/j.beem.2024.101938","url":null,"abstract":"Phaeochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumours with a strong genetic predisposition, involving over 20 genes and with germline pathogenic variants identified in 40 % of cases. The succinate dehydrogenase () genes are the most commonly implicated in hereditary PPGLs, accounting for 20 % of cases, and present unique diagnostic and treatment challenges due to their potential for multiple, recurrent, and aggressive manifestations, often necessitating lifelong follow-up. Over the past two decades, advances in biochemical and imaging assessments, management, and follow-up protocols have significantly improved care for both adult and paediatric patients. These advances include next-generation sequencing, new biochemical tests, cluster-specific functional imaging, and improved surgical and radiotherapy techniques, such as stereotactic surgery and peptide receptor radionuclide therapy (PRRT). International consensus guidelines have been developed to standardise the management of patients with pathogenic variants, emphasising multidisciplinary approaches and frequent tumour board discussions. These guidelines, summarised below, cover recommendations for initial genetic testing, tumour screening, follow-up care, and management of patients and asymptomatic carriers.","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":null,"pages":null},"PeriodicalIF":7.4,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142267231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The implications of hormone treatment for cancer risk, screening and treatment in transgender individuals 激素治疗对变性人患癌风险、筛查和治疗的影响。

IF 6.1 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2024-09-01 DOI: 10.1016/j.beem.2024.101909

引用次数: 0

Testosterone-induced erythrocytosis in transgender males: Challenges arising from an increasing prevalence of metabolic syndrome and wider therapeutic indications for prescribing SGLT2 inhibitor drugs 变性男性睾酮诱发的红细胞增多症：代谢综合征发病率上升带来的挑战以及 SGLT2 抑制剂药物处方治疗适应症的扩大。

IF 6.1 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2024-09-01 DOI: 10.1016/j.beem.2024.101930

引用次数: 0

Gender-affirming hormone treatment modalities for transfemale & non-binary transfeminine individuals: A UK perspective 针对变性女性和非二元变性女性的性别确认激素治疗模式：英国视角。

IF 6.1 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2024-09-01 DOI: 10.1016/j.beem.2024.101921

{"title":"Gender-affirming hormone treatment modalities for transfemale & non-binary transfeminine individuals: A UK perspective","authors":"","doi":"10.1016/j.beem.2024.101921","DOIUrl":"10.1016/j.beem.2024.101921","url":null,"abstract":"<div><p>Gender incongruence and the number of people seeking gender affirming hormone treatment has dramatically risen in the last two decades. In the UK, transgender women and non-binary transfeminine individuals are typically treated with simultaneous suppression of endogenous testosterone production through anti-androgens and exogenous oestradiol replacement. Oestrogen replacement comes in different forms and is primarily given as transdermal (gel or patch) or oral preparations in the UK. Decisions around preparation choice are based on a combination of individual preference and/or mitigating the chance of complications based on individual risk profiles. Time frames to achieve female physical changes are largely predictable and managing expectations of individuals prior to commencing treatment is highly important. Common complications include venous thromboembolism, liver dysfunction and effects on fertility, thus individuals should be thoroughly counselled prior to commencing treatment. This article provides an overview of the management and considerations of gender-affirming hormone treatment in transgender women and non-binary transfeminine individuals.</p></div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":null,"pages":null},"PeriodicalIF":6.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1521690X24000757/pdfft?md5=54468a8b1e776408fb77978d3bcbacc2&pid=1-s2.0-S1521690X24000757-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142134738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metabolic and cardiovascular risks of hormone treatment for transgender individuals 变性人接受激素治疗的代谢和心血管风险。

IF 6.1 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2024-09-01 DOI: 10.1016/j.beem.2024.101907

{"title":"Metabolic and cardiovascular risks of hormone treatment for transgender individuals","authors":"","doi":"10.1016/j.beem.2024.101907","DOIUrl":"10.1016/j.beem.2024.101907","url":null,"abstract":"<div><p>Identifying metabolic and cardiovascular risks of gender-affirming hormone therapy (GAHT) is challenging due to other confounding variables that affect patient outcomes and the diversity of treatment regimes. Masculinising hormone therapy produces atherogenic lipid profiles, while effects on other metabolic parameters are not consistent. There is insufficient evidence to conclude if cardiovascular disease risk among transmen is increased. The effects of feminising hormone therapy on metabolic parameters do not demonstrate a consistent pattern in the available literature. However, the risk of venous thromboembolism is greater in transwomen than in cis-gender men and women with a possible increase in cardiovascular disease risk. It is recommended to discuss the potential effects of GAHT on cardiovascular health and encourage patients seeking GAHT to adopt a healthy lifestyle. Performing baseline and periodic assessments of cardiovascular risk factors would enable early identification and interventions. In high-risk individuals, the cardiovascular effects of hormonal regimes might impact the treatment decision.</p></div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":null,"pages":null},"PeriodicalIF":6.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1521690X24000617/pdfft?md5=b527309d0293b6e0c81e36d80cdd71af&pid=1-s2.0-S1521690X24000617-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141473455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical considerations and endocrinological implications in the detransition process 脱胎换骨过程中的临床考虑因素和内分泌学影响。

IF 6.1 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2024-09-01 DOI: 10.1016/j.beem.2024.101932

引用次数: 0

Testosterone and other treatments for transgender males and non-binary trans masculine individuals 针对变性男性和非二元变性男性的睾丸激素和其他治疗方法。

IF 6.1 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2024-09-01 DOI: 10.1016/j.beem.2024.101908

引用次数: 0

Transgender 变性人

IF 6.1 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2024-09-01 DOI: 10.1016/j.beem.2024.101933

引用次数: 0